Coronary Artery Disease and Myocardial Infarction

ACC 23: Lipid Management & the CLEAR Trial with Dr Michos

Erin D Michos,

Watch time: 5m 34s
View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 36s
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients

Christie Ballantyne,

Watch time: 3m 44s
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s
AHA 22 Late-Breaker Discussion: The PRECISE Trial

Pamela S Douglas, Harriette Van Spall,

Watch time: 14m 56s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Salim S Virani, Ankur Kalra,

Listen time: 46m 28s
TCT 22: FAME 3: FFR-Guided PCI Vs CABG in Pts With Multivessel CAD

Yuhei Kobayashi,

Watch time: 7m 21s

Heather Currie , Christine Williams ,

Edward T Carreras , Donna M Polk ,

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Charles H Hennekens , Danielle Hollar , Arthur S Agatston ,

Sergio Fazio ,

Marc Sirol ,

Abdulah Alrifai , Mohamad Kabach , Jonathan Nieves , et al

Donald E Cutlip ,

Antonio Gutierrez , Sunil V Rao ,

Marsha M Neumyer , Bill Bertolino ,

Watch time: 1h 7m 2s (4 videos)

Media

ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Watch time: 1h 7m 2s (4 videos)
ACC 2022 Late-breaker Discussion: The SuperWIN Trial

Dylan L Steen, Harriette Van Spall,

Watch time: 16m 57s
RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes

Nick Curzen,

Watch time: 10m 53s
ACC 2021: Findings From the RESCUE Trial

Paul M Ridker,

Watch time: 9m 28s
TCT Connect 2020 Discussion: The VOYAGER PAD Study

Mirvat Alasnag, ,

Watch time: 17m 13s

Media

ACC 23: Lipid Management & the CLEAR Trial with Dr Michos

Erin D Michos,

Watch time: 5m 34s
View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 36s
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients

Christie Ballantyne,

Watch time: 3m 44s
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s
AHA 22 Late-Breaker Discussion: The PRECISE Trial

Pamela S Douglas, Harriette Van Spall,

Watch time: 14m 56s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Salim S Virani, Ankur Kalra,

Listen time: 46m 28s
TCT 22: FAME 3: FFR-Guided PCI Vs CABG in Pts With Multivessel CAD

Yuhei Kobayashi,

Watch time: 7m 21s
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Watch time: 1h 7m 2s (4 videos)
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Watch time: 7m 9s
Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Paul M Ridker,

Watch time: 10m 24s
ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab

Lorenz Räber,

Watch time: 6m 3s
ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)

Steven E Nissen,

Watch time: 3m 31s
ACC 22: Results from the TRANSLATE-TIMI 70 Trial

Watch time: 3m 54s
ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease

Frederik Zimmermann,

Watch time: 3m 6s
ACC 2022 Late-breaker Discussion: The SuperWIN Trial

Dylan L Steen, Harriette Van Spall,

Watch time: 16m 57s
RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes

Nick Curzen,

Watch time: 10m 53s
ACC 2021: Findings From the RESCUE Trial

Paul M Ridker,

Watch time: 9m 28s
ACC 2021 Discussion: The STRENGTH Study

Steven E Nissen, Harriette Van Spall,

Watch time: 9m 1s
What to Expect at TCTAP 2021

Bill D Gogas, Duk-Woo Park,

Watch time: 8m 28s
AHA 2020: The STRENGTH Trial

Watch time: 9m 40s
AHA 2020: Evinacumab safety and efficacy in HoFH

Watch time: 7m 44s
TCT Connect 2020 Discussion: The VOYAGER PAD Study

Mirvat Alasnag, ,

Watch time: 17m 13s

Articles

CTA and MPI—A Comparison in Detecting Significant Coronary Artery Disease

Matthew J Budoff

,

Ambarish Gopal

,

Citation:

US Cardiology 2006;3(2):1–6

  • Views: Views 1541
  • Downloads: Downloads 8